Permissive central tolerance plus defective peripheral checkpoints license pathogenic memory B cells in CASPR2-antibody encephalitis

Bo Sun, Dominique Fernandes, John Soltys, Anne-Kathrin Kienzler, Sofija Paneva, Ruby Harrison, Sudarshini Ramanathan, Anna L. Harrison, Mateusz Makuch, Miriam L. Fichtner, Robert F. Donat, Deniz Akdeniz, Halwan Bayuangga, Min Gyu Im, Robyn Williams, Ana Vasconcelos, Selina Thomsen, Andrew Fower, Ruyue Sun, Hannah Fox, Victor Mgbachi, Alexander Davies, Mandy Tseng, Adam Handel, Mark Kelly, Meng Zhao, James Bancroft, Rachael Bashford-Rogers, John V. Pluvinage, Ravi Dandekar, Bonny D. Alvarenga, Lynn B. Dustin, Simon Rinaldi, Ray Owens, Daniel Anthony, David L. Bennett, Patrick Waters, Simon J. Davis, Michael R. Wilson, Kevin C. O’Connor, Ana Luisa Carvalho, Sarosh R. Irani
Sci. Adv.. 2025-04-18; 11(16):
DOI: 10.1126/sciadv.adr9986

PubMed
Lire sur PubMed



Autoantibody-mediated diseases targeting one autoantigen provide a unique opportunity to comprehensively understand the development of disease-causing B cells and autoantibodies. Convention suggests that such autoreactivities are generated during germinal center reactions. Here, we explore earlier immune checkpoints, focusing on patients with contactin-associated protein-like 2 (CASPR2)–autoantibody encephalitis. In both disease and health, high (~0.5%) frequencies of unmutated CASPR2-reactive naïve B cells were identified. By contrast, CASPR2-reactive memory B cells were exclusive to patients, and their B cell receptors demonstrated affinity-enhancing somatic mutations with pathogenic effects in neuronal cultures and mice. The unmutated, precursor memory B cell receptors showed a distinctive balance between strong CASPR2 reactivity and very limited binding across the remaining human proteome. Our results identify permissive central tolerance, defective peripheral tolerance, and autoantigen-specific tolerance thresholds in humans as sequential steps that license CASPR2-directed pathology. By leveraging the basic immunobiology, we rationally direct tolerance-restoring approaches, with an experimental paradigm applicable across autoimmunity.

Auteurs Bordeaux Neurocampus